GlassScriptPhysician profile
Niruban Nirthananthan
NPI 1710465810
$3,001.27
in general payments reported to CMS, 2019-2025
23 companies · $960 in 2025
The $960 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.19 · 2022: $347 · 2023: $773 · 2024: $893 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,625.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $363.95 | 2021-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $311.84 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $259.79 | 2022-2024 | |
| Lilly USA, LLC | $258.35 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Eisai INC. | $236.79 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $236.53 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $203.40 | 2024-2025 | Breztri, Farxiga, Andexxa |
| Glaxosmithkline, LLC. | $173.35 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $166.12 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $141.54 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $117.01 | 2023-2025 | Verquvo, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.91 | 2022-2025 | Jardiance, Tradjenta |
| Phathom Pharmaceuticals, INC. | $69.36 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $67.18 | 2023-2025 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $63.44 | 2025 | Austedo Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $60.94 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $50.02 | 2023-2024 | Rexulti |
| Pfizer INC. | $35.09 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $16.94 | 2025 | Gemtesa |
| Ardelyx, INC. | $16.62 | 2025 | Ibsrela |
| Biogen, INC. | $14.47 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.42 | 2023 | Keveyis |
| Janssen Pharmaceuticals, INC | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niruban Nirthananthan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.